|
This activity has been designed to meet the educational
needs of oncology registered nurses.
The epidermal growth factor receptor (EGFR) pathway plays
a critical role in the processes involved in tumor growth
and progression and has been identified as a potential target
for cancer therapy. In recent years, three EGFR inhibitors
were approved for the treatment of colorectal and non-small
cell lung cancer, and many others are under investigation
for the treatment of solid tumors. Understanding the mechanisms
of action of EGFR inhibitors, as well as their administration
guidelines and side effect profiles, is important for optimal
care of patients receiving these novel therapies.
Provide education to oncology nurses on the role of the
EGFR pathway in tumor growth and progression, mechanisms
of action of agents targeting EGFR, current indications
for EGFR inhibitors in clinical practice, and their administration
guidelines and side effect profiles.
Upon completion of this program, participants should be
able to:
- Discuss the role of EGFR in carcinogenesis and tumor
progression
- Identify the current indications for EGFR inhibitors
- Describe nursing administration guidelines for EGFR
inhibitors
- List side effects of the EGFR inhibitors
Debra Wujcik, RN, MSN, AOCN®
Director, Clinical Trials Training and
Outreach
Vanderbilt-Ingram Cancer Center
This educational activity for 1.8 contact hours is provided
by the Postgraduate Institute for Medicine. Postgraduate
Institute for Medicine is an approved provider of continuing
education by the Colorado Nurses Association, an accredited
approver by the American Nurses Credentialing Center’s
Commission on Accreditation.
The Postgraduate Institute for Medicine is approved by the
California Board of Registered Nursing, Provider Number
13485 for 1.8 contact hours.
|
Postgraduate Institute for Medicine has a conflict of interest
policy that requires course faculty to disclose any real
or apparent commercial financial affiliations related to
the content of their presentations/materials. It is not
assumed that these financial interests or affiliations will
have an adverse impact on faculty presentations; they are
simply noted here to fully inform participants.
Debra Wujcik, RN, MSN, AOCN®, has a financial interest/relationship
or affiliation in the form of: Speakers’ Bureau, Amgen
Inc., Merck & Co., Inc., Bristol-Myers Squibb Company;
Nurse Advisory Board, Bristol-Myers Squibb Company and ImClome
Systems Incorporated.
There are no fees for participating and receiving CNE credit
for this activity. During the period May, 2005 through May,
2006, participants must: 1) read the learning objectives
and faculty disclosures; 2) study the educational activity;
3) complete the post-test by recording the best answer to
each question in the answer key on the evaluation form;
4) complete the evaluation form; and 5) mail or fax the
evaluation form and post-test to Postgraduate Institute
for Medicine.
A statement of credit will be issued only upon receipt
of a completed activity evaluation form and a completed
post-test with a score of 70% or better. Your statement
of credit will be mailed to you within three weeks.
Printed Newsletter
This educational activity may contain discussion of published
and/or investigational uses of agents that are not indicated
by the FDA. Postgraduate Institute for Medicine (PIM), Institute
for Medical Education & Research, Inc. (IMER), Bristol-Myers
Squibb Company, and ImClone Systems Incorporated do not
recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those
of the faculty and do not necessarily represent the views
of PIM, IMER, Bristol-Myers Squibb Company, or ImClone Systems
Incorporated. Please refer to the official prescribing information
for each product for discussion of approved indications,
contraindications, and warnings.
Participants have an implied to use the newly acquired enhance
patient outcomes professional development. presented in
this activity serve as a guideline for management. Any procedures,
courses of diagnosis or or suggested in this activity used
by clinicians without patients’ conditions and contraindications
on dangers in applicable manufacturer’s information,
and comparison of other authorities.
|
